Thrombotic Microangiopathy
📧 Sign up to get email alerts when something new happens for Thrombotic Microangiopathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant [Phase 3]
A Phase 3 trial evaluating Ravulizumab for thrombotic microangiopathy after hematopoietic stem cell transplantation has completed.
-
CLINICAL_TRIALS trial_result · 2026-01-16Clinical Trial Update: Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy [NA]
This clinical trial update states that iptacopan is being studied for high-risk transplantation-associated thrombotic microangiopathy and th…
-
CLINICAL_TRIALS trial_result · 2025-12-10Clinical Trial Update: Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome [Phase 3]
A Phase 3 safety and efficacy trial of OMS721 in patients with atypical hemolytic uremic syndrome has been terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy [Phase 3]
Phase 3 trial of Nomacopan for transplant-associated thrombotic microangiopathy was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2024-08-28Clinical Trial Update: Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies [Phase 2]
Phase 2 safety and efficacy study of OMS721 in thrombotic microangiopathies has completed. Results of the trial have been posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-12-12Clinical Trial Update: Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger [Phase 3]
Phase 3 clinical trial evaluating ravulizumab for thrombotic microangiopathy associated with a trigger was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2023-01-27Clinical Trial Update: Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies [Phase 3]
Pilot multicenter trial evaluating eculizumab for gemcitabine-induced thrombotic microangiopathy; phase 3, status unknown.
-
CLINICAL_TRIALS trial_result · 2023-01-04Clinical Trial Update: Ravulizumab and COVID-19 [Phase 3]
A Phase 3 clinical trial update for ravulizumab in COVID-19 and related thrombotic microangiopathy conditions; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2022-02-14Clinical Trial Update: A Safety and Efficacy Study of NAC in Patients With TA-TMA [Phase 3]
Phase 3 trial evaluating NAC for thrombotic microangiopathy shows completed status with posted results.
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Defibrotide TMA Prophylaxis Pilot Trial [Phase 2]
Phase 2 pilot trial evaluating defibrotide for prophylaxis of thrombotic microangiopathy has completed and results were posted.
-
CLINICAL_TRIALS trial_result · 2018-03-30Clinical Trial Update: Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
This completed clinical trial (NCT02604420) investigates approaches to identify and treat thrombotic microangiopathy following allogeneic st…
-
CLINICAL_TRIALS trial_result · 2017-08-11Clinical Trial Update: Promising Bimarker Prediction of Outcome of HELLP Syndrome.
A completed clinical trial reports that certain biomarkers may predict outcomes in HELLP syndrome, potentially aiding prognosis in severe pr…
-
CLINICAL_TRIALS trial_result · 2017-07-28Clinical Trial Update: Immature Platelet Fraction as a Promising Biomarker in Prediction Outcome of HELLP Syndrome
This clinical trial update reports that immature platelet fraction may serve as a biomarker to predict outcomes in HELLP syndrome, and the s…
-
CLINICAL_TRIALS trial_result · 2009-11-26Clinical Trial Update: Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy [Phase 2]
A Phase 2 clinical trial evaluating ARC1779 for thrombotic microangiopathy was terminated.